Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?
BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …